Filing Details
Travere Therapeutics, Inc. (NASDAQ:TVTX) filed a Form 8-K with the Securities and Exchange Commission on July 09, 2026, disclosing a material event.
8k filedNASDAQ:TVTX
Travere Therapeutics, Inc. (TVTX) Reports Material Event to SEC
Filing Details Travere Therapeutics, Inc. (NASDAQ:TVTX) filed a Form 8-K with the Securities and Exchange Commission on July 09, 2026, disclosing a material event. Market Context…
Market Context
Travere Therapeutics, Inc.'s stock currently trades at $58.47 with a market capitalization of $3.1B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Travere Therapeutics, Inc.'s stock.
All SEC filings for Travere Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TVTX Stock Page
Frequently Asked Questions
Where can I read TVTX's SEC filings?
Browse all filings on our TVTX SEC filings page.
What types of SEC filings does Travere Therapeutics, Inc. file?
Public companies like Travere Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.